Lyell Immunopharma annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Free Cash Flow (FCF) History (LYEL)
Lyell Immunopharma reported −$150.8M in free cash flow for fiscal 2025, an increase of $12.1M from the previous fiscal year, with a free cash flow margin of −418900.00%.
View full Lyell Immunopharma company overviewLyell Immunopharma free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$150.8M | $12.1M | — | −418900.00% |
| 2024 | 2024-12-31 | −$162.9M | $3.5M | — | −266980.33% |
| 2023 | 2023-12-31 | −$166.4M | $27.5M | — | −127984.62% |
| 2022 | 2022-12-31 | −$193.8M | −$2.1M | — | −228.89% |
| 2021 | 2021-12-31 | −$191.8M | $20.6M | — | −1800.50% |
| 2020 | 2020-12-31 | −$212.4M | −$235.8M | — | −2737.94% |
| 2019 | 2019-12-31 | $23.4M | — | — | +3565.75% |
Lyell Immunopharma quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$34.2M | $448,000 | — | −854450.00% |
| Q1 2026 | 2026-03-31 | −$38.6M | $16.4M | — | −1929950.00% |
| Q4 2025 | 2025-12-31 | −$32.6M | $14.7M | — | −542583.33% |
| Q3 2025 | 2025-09-30 | −$28.6M | $6.5M | — | −190926.67% |
| Q2 2025 | 2025-06-30 | −$34.6M | $3.8M | — | −432825.00% |
| Q1 2025 | 2025-03-31 | −$55.0M | −$12.9M | — | −785485.71% |
| Q4 2024 | 2024-12-31 | −$47.3M | −$6.6M | — | −429872.73% |
| Q3 2024 | 2024-09-30 | −$35.1M | $2.8M | — | −103238.24% |
| Q2 2024 | 2024-06-30 | −$38.4M | $1.7M | — | −295576.92% |
| Q1 2024 | 2024-03-31 | −$42.0M | $5.7M | — | −1401533.33% |
| Q4 2023 | 2023-12-31 | −$40.7M | $4.2M | — | −312769.23% |
| Q3 2023 | 2023-09-30 | −$37.9M | $2.0M | — | −151524.00% |
| Q2 2023 | 2023-06-30 | −$40.1M | $11.4M | — | −148496.30% |
| Q1 2023 | 2023-03-31 | −$47.7M | $9.8M | — | −73453.85% |
| Q4 2022 | 2022-12-31 | −$44.8M | −$1.4M | — | −92.69% |
| Q3 2022 | 2022-09-30 | −$39.9M | −$2.8M | — | −1329800.00% |
| Q2 2022 | 2022-06-30 | −$51.5M | $6.9M | — | −144.10% |
| Q1 2022 | 2022-03-31 | −$57.6M | −$4.8M | — | −10413.20% |
| Q4 2021 | 2021-12-31 | −$43.5M | −$9.2M | — | −1540.79% |
| Q3 2021 | 2021-09-30 | −$37.1M | — | — | −1346.32% |
| Q2 2021 | 2021-06-30 | −$58.4M | — | — | −2221.99% |
| Q1 2021 | 2021-03-31 | −$52.8M | — | — | −2158.98% |
| Q3 2020 | 2020-09-30 | −$34.3M | — | — | −3202.71% |
Lyell Immunopharma free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$212.4M to −$150.8M, a net increase of $61.6M. Lyell Immunopharma's latest reported quarter, Q2 2026, generated −$34.2M in free cash flow, an increase of $448,000 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Lyell Immunopharma filings at SEC.gov ↗